These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 24361258)
1. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Lughezzani G; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Fossati N; Lista G; Larcher A; Abrate A; Mistretta A; Bini V; Palou Redorta J; Graefen M; Guazzoni G Eur Urol; 2014 Nov; 66(5):906-12. PubMed ID: 24361258 [TBL] [Abstract][Full Text] [Related]
2. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]
4. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975 [TBL] [Abstract][Full Text] [Related]
6. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786 [TBL] [Abstract][Full Text] [Related]
8. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study. Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357 [TBL] [Abstract][Full Text] [Related]
9. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305 [TBL] [Abstract][Full Text] [Related]
10. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062 [TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080 [TBL] [Abstract][Full Text] [Related]
12. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013 [TBL] [Abstract][Full Text] [Related]
13. Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. Foj L; Filella X Clin Chim Acta; 2020 Feb; 501():174-178. PubMed ID: 31758936 [TBL] [Abstract][Full Text] [Related]
14. Validation of the prostate health index in a predictive model of prostate cancer. Sanchís-Bonet A; Barrionuevo-González M; Bajo-Chueca AM; Pulido-Fonseca L; Ortega-Polledo LE; Tamayo-Ruiz JC; Sánchez-Chapado M Actas Urol Esp (Engl Ed); 2018; 42(1):25-32. PubMed ID: 28811062 [TBL] [Abstract][Full Text] [Related]
15. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248 [TBL] [Abstract][Full Text] [Related]
16. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138 [TBL] [Abstract][Full Text] [Related]
19. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131 [TBL] [Abstract][Full Text] [Related]
20. Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process? Sanchis-Bonet A; Barrionuevo-González M; Bajo-Chueca A; Morales-Palacios N; Sanchez-Chapado M Urol Int; 2018; 100(2):146-154. PubMed ID: 29346783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]